Cambium Bio Limited (ASX: CMB)
Health Care · Biotechnology · AU
AU$0.45
-16.67% today · -6.2% 1Y
Cambium Bio Limited (ASX: CMB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.22M and employs 2 people.
Over the last twelve months the share price has lost 6.2%, trading between 0.34 and 0.60.
Tweenvest scores Cambium Bio Limited across four factors: quality 42/100, value 65/100. Its strongest factor is value.
CMB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.22M
- Revenue (TTM)
- $847.90K
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- -0.52
- 52-week high
- AU$0.60
- 52-week low
- AU$0.34
- Avg volume (3M)
- —
- Shares outstanding
- 29.43M
- Employees
- 2
- Next earnings
- —
About Cambium Bio Limited
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
- ISIN
- AU0000327769
- Listed since
- Dec 12, 2016
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PeopleBio, Inc.KOSDAQ: A304840 | $9.47M | ₩— | — |
| AtonENXTPA: ALTAO | $9.46M | €0.01 | -5.56% |
| Lisata Therapeutics, Inc.NasdaqCM: LSTA | $9.28M | $1.03 | -2.83% |
| Celestra Inc.KOSDAQ: A352770 | $9.28M | ₩— | — |
| Spago Nanomedical AB (publ)OM: SPAGO | $9.19M | Skr0.11 | +12.32% |
| BioVie Inc.NasdaqCM: BIVI | $9.05M | $1.20 | -13.67% |
| Hemostemix Inc.TSXV: HEM | $8.97M | CA$0.06 | -20.00% |
| Poxel S.A.ENXTPA: POXEL | $8.95M | €0.15 | +10.45% |
Figures last refreshed Oct 18, 2026.